16:05 EDT Tvardi Therapeutics (TVRD) files to sell 2.08M shares of common stock for holders
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Buy Rating for Tvardi Therapeutics Driven by Promising Phase 2 Trial Results and Growth Potential
- Tvardi Therapeutics completes enrollment in TTI-101 trial
- Tvardi Completes Enrollment for Phase 2 IPF Trial
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Tvardi Therapeutics initiated with an Outperform at Oppenheimer